Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term [Seeking Alpha]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Seeking Alpha
Summary Avidity Biosciences, Inc.'s stock surged ~650% in the past year, driven by positive developments in its Antibody Oligonucleotide Conjugates (AOCs) for muscular disorders. Key catalysts include a lucrative $2.3 billion partnership with Bristol Myers Squibb and positive long-term data from the MARINA OLE study for DM1. AOC-1001 shows promise in treating myotonic dystrophy Type 1, with the Phase 3 HARBOR trial underway, and additional candidates in clinical trials for FSHD and DMD. Strategic partnerships with Bristol Myers and Eli Lilly bolster Avidity's financial and developmental prospects, enhancing its investment appeal. Ultimately, however, a “wait and see” approach may be the right strategy to adopt with near-term catalysts absent and bigger market opportunities presenting themselves in a few years' time, potentially. Michail_Petrov-96 Investment Overview Avidity Biosciences, Inc. NASDAQ: RNA ) is one of the top-performing biotech stocks of the past year, i
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $72.00 price target on the stock.MarketBeat
- Avidity Biosciences to Participate in Upcoming Investor ConferencePR Newswire
- Avidity Biosciences, Inc. (NASDAQ: RNA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $67.00 price target on the stock.MarketBeat
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
RNA
Earnings
- 8/9/24 - Beat
RNA
Sec Filings
- 12/19/24 - Form 4
- 12/19/24 - Form 4
- 12/19/24 - Form 4
- RNA's page on the SEC website